DNA vaccine protects against toxic proteins linked to Alzheimer's

May 23, 2017
UT Southwestern researchers have developed a DNA vaccine that helps the body protect against toxic proteins associated with Alzheimer's disease. These images show amyloid plaque in the mouse brain using plasma containing anti-amyloid antibody from large mammals immunized with the vaccine. Credit: UT Southwestern

A new DNA vaccine when delivered to the skin prompts an immune response that produces antibodies to protect against toxic proteins associated with Alzheimer's disease - without triggering severe brain swelling that earlier antibody treatments caused in some patients.

Two studies from the Peter O'Donnell Jr. Brain Institute demonstrate in animals how a vaccine containing DNA of the toxic beta-amyloid protein elicits a different immune response that may be safe for humans.

The vaccine, which will likely be tested further by the U.S. Food and Drug Administration, is on a shortlist of promising antibody treatments that may eventually help settle a high-stakes debate of whether amyloid is a vital target for preventing or curing Alzheimer's.

"If you look at the hard reality, the odds are against us because so many therapies have failed through the years. But this has potential," said Dr. Roger Rosenberg, co-author of the studies and Director of the Alzheimer's Disease Center at UT Southwestern Medical Center.

Dr. Rosenberg notes that earlier research established that antibodies significantly reduce amyloid buildup in the brain, but he needed to find a safe way to introduce these into the body. A vaccine developed elsewhere showed promise in the early 2000s, but when tested in humans it caused brain swelling in some patients.

Dr. Rosenberg's idea was to start with DNA coding for amyloid and inject it into the skin rather than the muscle. The injected skin cells make the , and the body responds by producing new antibodies that inhibit the buildup of amyloid, which some scientists blame for destroying neurons.

Although the DNA vaccine has not yet been tested in humans, it produces a different kind of immune response in the tested animals that significantly lessens the chance of an adverse response in the brain, according to the studies published in the Journal of Alzheimer's Disease and Alzheimer's Research & Therapy.

The research is notable because it shows a DNA vaccine can be effective and safe in two large mammals. Most other vaccines only produced an immune response in mice but not large mammals.

"We believe this kind of immune response has a high probability of being safe in humans and also being effective to make high levels of antibody," said Dr. Rosenberg, Professor of Physiology, Neurology and Neurotherapeutics.

Alzheimer's disease is characterized by progressive deterioration of the brain as neurons are destroyed. More than 5 million Americans have the fatal disease, with the number expected to nearly triple by 2050, according to the Centers for Disease Control and Prevention.

No known cure exists, though an array of antibody and other treatments are being researched to target amyloid plaques. One strategy involves preforming the antibodies in the laboratory and inserting them into the body - a technique that is still being tested for clinical benefits.

Dr. Rosenberg said there would be distinct advantages to allowing the body to produce its own antibodies through active immunization, if it can be done safely. Among them, the vaccine would be more accessible and less expensive. It also produces a wider variety of antibody types than the preformed antibodies, he said.

"All the vaccines we received as kids and adults have been active vaccinations; we made the antibodies in the body," Dr. Rosenberg said. "It's safer, more effective, and it's sustained longer."

Dr. Rosenberg's research is the latest contribution to decades of study across the globe focusing on clearing amyloid plaques in hopes of curing or slowing the progression of Alzheimer's. A lack of results over the years has prompted some scientists to question whether they are properly targeting the disease.

A British study from 2008 showed that removing amyloid after it accumulates in the brain does not improve brain cognition. The findings highlight a couple of lingering questions that have crucial implications for the future of Alzheimer's research: Is amyloid merely a symptom, not the cause of the disease? And if there is causation, can earlier treatments make a difference?

Dr. Rosenberg acknowledges that preventing amyloid buildup by itself may not be an adequate treatment for Alzheimer's, but it could be a major part of the solution. He and other researchers at UT Southwestern are also studying the potential benefits of preventing and removing tangles of toxic tau proteins from the , another hallmark of the disease.

"Some in the scientific community believe the reason amyloid therapies have failed so far is because too little of the therapy was given, and too late," Dr. Rosenberg said. "The jury is still out."

Dr. Rosenberg's latest studies show the potential of a DNA vaccine to prevent the buildup of amyloid in otherwise healthy people. The vaccine was administered to healthy animals, inducing an anti-inflammatory of up to 40 times more anti- than an earlier vaccine Dr. Rosenberg tested a decade ago.

Dr. Rosenberg expects the FDA will want further tests of the vaccine in its own labs before planning a potential clinical trial on people. If proven effective, the could be given to people who are at risk of developing Alzheimer's but have not yet started forming .

Dr. Rosenberg keeps his expectations in check, noting the billions of dollars and multitude of studies that have so far yielded little advancement in treating Alzheimer's disease.

"Finding answers to this will knock you down fast," said Dr. Rosenberg, who has worked at UT Southwestern for 44 years and holds the Abe (Brunky), Morris and William Zale Distinguished Chair in Neurology. "I've made a commitment to this place and to this research. I'm trying, and I'll keep going."

Explore further: The first-in-man clinical trial targeting Alzheimer's Tau protein

Related Stories

The first-in-man clinical trial targeting Alzheimer's Tau protein

December 12, 2016
For the first time, targeting the other feature of Alzheimer's disease, tau, has given fruitful results. In an unprecedented study, active vaccination in humans has resulted in a favorable immune response in 29 out of the ...

Possible solution for side effect of Alzheimer's immunotherapy treatment

November 5, 2015
It is estimated that 46.8 million people worldwide are living with dementia, with Alzheimer's disease the most common form.

Alzheimer's vaccine triggers brain inflammation when brain amyloid burden is high

November 14, 2011
Patients with Alzheimer's disease who are in the early stages of their illness will likely benefit most from vaccine therapies now being tested in a number of human clinical trials, say researchers from Georgetown University ...

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Two amyloid-beta antibodies found to cause neuronal dysfunction in mice

November 10, 2015
(Medical Xpress)—A team of researchers working in Germany has found that giving two different types of amyloid-β antibodies to mice genetically engineered to have Alzheimer's type symptoms caused them to develop a type ...

Recommended for you

Delayed word processing could predict patients' potential to develop Alzheimer's disease

October 20, 2017
A delayed neurological response to processing the written word could be an indicator that a patient with mild memory problems is at an increased risk of developing Alzheimer's disease, research led by the University of Birmingham ...

PET scans for Alzheimer's could bring benefit to more patients

October 19, 2017
An imaging tool honed to spot rogue proteins in the brain could benefit some patients with suspected Alzheimer's, according to a new study.

One step closer toward a treatment for Alzheimer's disease?

October 18, 2017
Scientists at the Massachusetts General Hospital (MGH), in collaboration with colleagues at the University California, San Diego (UCSD), have characterized a new class of drugs as potential therapeutics for Alzheimer's disease ...

New mechanism detected in Alzheimer's disease

October 13, 2017
McGill University researchers have discovered a cellular mechanism that may contribute to the breakdown of communication between neurons in Alzheimer's disease.

Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer's disease

October 13, 2017
Microglia, immune cells that act as the central nervous system's damage sensors, have recently been implicated in Alzheimer's disease.

Green tea extract delivers molecular punch to disrupt formation of neurotoxic species

October 11, 2017
Green tea is widely considered to be beneficial for the brain. The antioxidant and detoxifying properties of green tea extracts help fight catastrophic diseases such as Alzheimer's. However, scientists have never fully understood ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

BubbaNicholson
1 / 5 (1) May 24, 2017
Alzheimer's Disease is caused by a poisonous pheromone usually emitted by angry or perhaps anxious relatives. Oscillating fans in areas of social contact with angry relatives may be all that is necessary to diminish risk to near zero.
Providing 250mg of healthy adult male facial skin surface lipid pheromone by mouth reverses some symptoms and halts progression of the disease. (Use extreme care in handling the skin surface lipid, as collected pheromone emits an airborne aversive sub-pheromone which causes emotional problems: arrogance, stupidity, incompetence, suspicion, superstition, and jealousy. Jealousy in the inevitable result of kissing osculation partners once treated, so isolate for 40 days until saliva is cleared of pheromone. Use sealed packaging with activated charcoal dunnage, fume hoods, supplied air respirators and oscillating fans to break up airborne plumes.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.